Pre-Made Bifikafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human IL2 (interleukin 2, IL-2) Pr21-153 (100%) (1:1), noncovalent dimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCF for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-761

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-761 Category Tag

Product Details

Pre-Made Bifikafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human IL2 (interleukin 2, IL-2) Pr21-153 (100%) (1:1), noncovalent dimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCF is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bifikafusp alfa is a fusion protein of pro-inflammatory IL-2 and IL19 human mAb fragment (scFv domain) that binds the tumor microenvironment expressed fibronectin extradomain B (EDB). Incorporation of the IL19 binding fragment targets the drug to the tumor, improving selective site accumulation and tumor killing and at the same time reducing the effective dose required to achieve a meaningful response, and reducing the otherwise dose-limiting toxicities associated with high-dose IL-2 administration that would be required to produce the same killing effect.

Products Name (INN Index)

Pre-Made Bifikafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human IL2 (interleukin 2, IL-2) Pr21-153 (100%) (1:1), noncovalent dimer: Recombinant therapeutic protein targeting CIG

INN Name

bifikafusp alfa

Target

FN

Format

Fusion Protein

Derivation

Human

Species Reactivity

Human

CH1 Isotype

scFv – heavy – kappa

VD LC

scFv – heavy – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Philogen (Sovicille Italy)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

FN

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide